Medios AGMEDOF 88 Return-on-Tangible-Equity is 55.83% as of Mar. 2026, which is 398% above its 10-year median of 11.21. GuruFocus rates MEDOF with a GF Score™ of 88/100 and a GF Value™ of $71.50. The stock has 2 warning signs investors should review. Among 111 Medical Distribution companies, Medios AG ranks better than 81.98% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medios AG's annualized net income for the quarter that ended in Mar. 2026 was $23 Mil. Medios AG's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $41 Mil. Therefore, Medios AG's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 55.83%.
The historical rank and industry rank for Medios AG's Return-on-Tangible-Equity or its related term are showing as below:
MEDOF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -24.29 Med: 11.21 Max: 102.86
Current: 50.38
During the past 13 years, Medios AG's highest Return-on-Tangible-Equity was 102.86%. The lowest was -24.29%. And the median was 11.21%.
MEDOF's Return-on-Tangible-Equity is ranked better than 81.98% of 111
companies
in the Medical Distribution industry
Industry Median: 9.07
vs MEDOF: 50.38
Medios AG (OTCPK:MEDOF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medios AG Return-on-Tangible-Equity Related Terms
Medios AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medios AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDOF vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Medios AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medios AG Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medios AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medios AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 55.83% mean?
Medios AG (MEDOF) has a Return-on-Tangible-Equity of 55.83% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medios AG and its competitors. This is 398% above median its historical median of 11.21. According to the industry distribution chart, Medios AG ranks #20 out of 111 companies in the Medical Distribution industry, placing it in the top 18%.
Is Medios AG's Return-on-Tangible-Equity too high?
Medios AG's current Return-on-Tangible-Equity of 55.83% is 398% above median its 10-year median of 11.21. The Medical Distribution industry median Return-on-Tangible-Equity is 9.07. Medios AG's value of 55.83% is 515.5% above this industry median. Based on the distribution chart, Medios AG ranks #20 out of 111 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Medios AG has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Medios AG's Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medios AG ranks #20 out of 111 companies for Return-on-Tangible-Equity. This places Medios AG in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 9.07. Medios AG's value of 55.83% is 515.5% above this benchmark. While the company's 10-year median is 11.21 vs. the industry median of 9.07, Medios AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 9.07, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medios AG's current Return-on-Tangible-Equity of 55.83% is 515.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medios AG and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 9.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medios AG's current Return-on-Tangible-Equity is 55.83%, which is 398% above median its own 10-year median of 11.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medios AG stock overvalued right now?
Medios AG (MEDOF) has a current Return-on-Tangible-Equity of 55.83%. The stock's GF Value™ is $71.50, compared to a current price of $50.00 — trading 30.1% below its estimated fair value. The current Return-on-Tangible-Equity is 55.83%, which is 398% above median its 10-year median of 11.21 and 515.5% above the Medical Distribution industry median of 9.07. Medios AG's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medios AG (MEDOF), the current Return-on-Tangible-Equity is 55.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medios AG (MEDOF) Overvalued in 2026?
Based on GuruFocus' analysis, Medios AG stock appears to be undervalued.
The current stock price of $50.00 is trading 30.1% below its estimated GF Value™ of $71.50.
Key valuation signals for MEDOF:
Return-on-Tangible-Equity: 55.83% (398% above median its 10-year median of 11.21)
GF Value™: $71.50 vs. price of $50.00 (30.1% below fair value)
Industry Position: 515.5% above the Medical Distribution median (#20 of 111)
No single metric tells the full story. See the MEDOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes: Patient-Specific Therapies: This area includes the compounding of medications on behalf of pharmacies in Germany. Pharmaceautical Supply: Medios is speciality pharma supplier company in germany, producing it own production facilities, hospitals, and Pharmacies. International Business: It includes all business and activities happening in international business.
88GF Score
Get the complete analysis for MEDOF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDOF has been successfully added to your 
